Ema Health, a company specialising in healthcare innovation, has announced that it has secured a \u20ac3 million investment round for its Rosso platform, with new shareholders and strategic investors joining the company.<\/p>\n\n
The round is led by 360 Capital through its 360 Digitaly fund, with support from Cassa Depositi e Prestiti Venture Capital via the Digital Transition Fund \u2013 PNRR, the public vehicle financed with NextGenerationEU funds and dedicated to the digital transition of Italian businesses in strategic sectors, including healthcare.<\/p>\n\n
The following are participating in the operation: Angelini Investments, Ciapa Rosso led by Giorgio Valerio and Alfredo Romano, Fintech Partners led by Giulio Gallazzi, founder of SRI Group, H-Farm led by Riccardo Donadon, Studio Necchio, as well as Adolfo Vannucci, Vitaliano Borromeo Arese Borromeo, Sebastiano Cavalieri Ducati, Massimo Protti, Stefano Barrese, Serra Elizabeth Falk, Edoardo Turkheimer, Sandro Berra, Daniele Far\u00e8 and Maria Domenica Pellegrini. <\/p>\n\n
Rosso was founded in 2023 following a meeting between two entrepreneurs active in the field of healthcare innovation: Chiara Schettino, an alumna of Ca\u2019 Foscari University \u2013 H-Farm College, and Filippo Toni. The founders have built a business that, in just two years, has engaged tens of thousands of donors across hundreds of blood collection centres nationwide and involved dozens of leading Italian companies in promoting blood health amongst their employees. With just a few taps on a smartphone, Rosso locates the nearest centre and allows users to book a blood or plasma donation quickly and easily, managing the entire process directly through the app. <\/p>\n\n
Chiara Schettino and Filippo Toni, founders of Ema Health and the Rosso platform (pictured), said in a statement: \u201cWe are excited about this new phase for the company, which, with the arrival of these new partners, is aiming for significant growth. This funding round enables us to scale up nationally and establish a technological benchmark for the blood and blood products system, first in Italy and then across Europe. Our goal is to support all organisations working in this field to facilitate and strengthen the blood donation system, a sector of vital importance to the country. We would like to thank our long-standing partners, our new investors and everyone who works with us every day to make all this possible.\u201d <\/p>\n\n
The Italian blood transfusion system operates on a voluntary and unpaid basis. In 2024, there were 1.67 million active donors, accounting for a total of 3 million donations (source: National Blood Centre; Italian Red Cross, June 2025). However, many donors are approaching the age of 65, the upper age limit for donation, and without a new generation of donors, the self-sufficiency achieved could be put at risk (source: National Blood Centre; May 2024); it is also important to note that young people obtain their information mainly through digital channels (source: Reuters Institute, Digital News Report 2025; Reuters Institute, Understanding Young News Audiences, 2026). <\/p>\n\n
Toni adds: \u201cIt is becoming increasingly clear that we need to find solutions that reach young people. Thanks to these investments, Rosso will be able to accelerate its growth, reaching an ever-increasing number of donors and gradually digitising blood transfusion facilities across the country.\u201d <\/p>\n\n
Lucrezia Lucotti, a partner at 360 Capital, comments: \u201cThe Italian blood transfusion system is a critical piece of infrastructure for the country, which for decades has lacked adequate technology.\u201d<\/strong> \u201cThis is exactly the kind of sector we believe in: one where digitalisation isn\u2019t an option but a necessity, and where the impact can be huge. Rosso is the answer this sector has been waiting for, and there\u2019s no one better than Chiara and Filippo to take it forward.\u201d <\/p>\n\n Sergio Marullo di Condojanni, CEO of Angelini Industries, says: \u201cMajor social challenges require innovation, expertise and the ability to nurture the talent of the younger generation.\u201d <\/strong>\u201cRosso demonstrates how young entrepreneurs can make a tangible contribution to strengthening an infrastructure that is essential to the healthcare system, thereby creating value for the community. That is why we have chosen to support a project that combines technology, entrepreneurship and social impact.\u201d <\/p>\n\n Giulio Gallazzi, Chairman of Fintech Partners, said: \u201cWe have chosen to support Rosso because it is a concrete example of how technology, entrepreneurial vision and social responsibility can come together to strengthen an innovative platform that is essential for the country. The digitalisation of the blood supply chain is a strategic challenge for the Italian healthcare system, and Rosso has very quickly demonstrated that it has the potential to contribute significantly to the system\u2019s efficiency and to engaging new generations of donors.\u201d<\/p>\n\n Rosso is an integrated digital ecosystem, powered by artificial intelligence, which guides donors through every stage of the process and supports organisations in the advanced planning and management of non-clinical activities. The protection of personal data, cybersecurity and the confidentiality of health information are an integral and fundamental part of the architecture of Ema Health\u2019s platforms, which have been designed from the outset in accordance with the principles of privacy by design and are periodically reviewed by industry experts. <\/p>\n\n With offices in Milan and Lucca, the Ema Health team comprises experienced professionals and young talent from Italian universities, with the aim of further strengthening the team in the coming months to support the company\u2019s growth.<\/p>\n","protected":false},"excerpt":{"rendered":" The platform aims to revolutionise the way people give blood; the funding round is led by 360 Capital<\/p>\n","protected":false},"author":125,"featured_media":175593,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"_substack_draft_id":"","_substack_draft_url":"","_substack_last_pushed":"","_substack_premium":"","footnotes":""},"categories":[1317],"tags":[1358,1143,1136,1145],"companies":[3505],"journalist":[1518],"class_list":["post-175594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-healthcare-en","tag-investments","tag-startup-en-2","tag-venture-capital-en-2","companies-ema-health","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/06\/rosso-piccola.jpg","width":150,"height":105,"crop":false,"srcset":false,"alt":"blood donation"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/06\/rosso-piccola.jpg","width":1024,"height":716,"crop":false,"srcset":false,"alt":"blood donation"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2026\/06\/rosso-piccola.jpg","width":1162,"height":812,"crop":false,"srcset":false,"alt":"blood donation"}},"acf":[],"yoast_head":"\n